<DOC>
	<DOCNO>NCT02417103</DOCNO>
	<brief_summary>The aim study investigate effect treatment GLP-1 Analogon Liraglutide lipid metabolism inflammation adipose tissue .</brief_summary>
	<brief_title>Pretreatment Patients Expecting Bariatric Surgery With GLP-1 Analogon Liraglutid</brief_title>
	<detailed_description>The aim study investigate effect treatment GLP-1 Analogon Liraglutide lipid metabolism inflammation adipose tissue . As GLP-1 presume improve insulin sensitivity associate parameter investigator hypothesize might due change lipid metabolism might involve regulation insulin sensitivity . Therefore investigator intend investigate change metabolic pathway treatment GLP-1 analog liraglutide could play crucial role pathogenesis well regulation insulin sensitivity atherogenic dyslipidemia : de novo lipogenesis reverse cholesterol transport</detailed_description>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<criteria>BMI 3555 Kg/m2 Fasting Blood glucose &gt; 140mg/dl Planned bariatric surgery Diabetic Medication ( Metformin , Sulfonylurea , Insuline ) Known hypersensitivity Liraglutid Pretreatment DPP4 Inhibitors GLP1 Analogue last 3 month HbA1c &gt; 10 %</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>77 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>